News

Pfizer's Oral Obesity Drug Flop - A Symptom Of A Deeper Pipeline Problem
Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...
Why Ozempic maker Novo Nordisk is losing its lead in weight-loss drugs
Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...
Novo Nordisk to launch weight-loss drug Wegovy in India ahead of schedule
Amid rising demand and Eli Lilly's Mounjaro launch, Novo Nordisk is advancing plans to introduce its obesity drug Wegovy in ...
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?
With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.
Novo Nordisk to launch blockbuster obesity drug Wegovy in India soon
"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide ...
Second Ashland weight loss clinic accused of administering non-FDA approved drugs
ASHLAND A weight loss clinic with multiple locations in Kentucky, including Ashland, is facing accusations of providing patients with non-FDA approved semaglutide — falsely advertising a compounded ...
Reshaping India’s waistline
Tirzepatide, the newest weight loss drug in India, is transforming the wellness market with its hormone-mimicking effects.